Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2018-11-21 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于对外投资进展暨签订投资合同的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the progress and signing of an investment contract related to external investments and the establishment of subsidiaries. It details the investment amount, project scope, board approvals, and risk factors. There are no financial statements, earnings data, or audit information. The content focuses on capital investment activities and contract signing, which aligns with updates on company fundraising or capital structure changes. The document length is about 2557 characters, which is relatively short but contains substantive information about the investment contract rather than just announcing a report publication. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2018-11-21 Chinese
第三届董事会第二十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 27th meeting of the third board of directors of the company. It includes details about the meeting date, attendance, and voting results on an investment contract. It does not contain detailed financial data, full management discussion, or comprehensive report content. It is an announcement related to board/management decisions and meeting resolutions, not a full report or financial statement. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on board meeting resolutions, confirming this classification.
2018-11-21 Chinese
关于部分理财产品到期赎回的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the progress of redemption of certain financial products (理财产品) that have matured. It details the amounts, dates, and yields of these financial products, as well as the associated risks and measures taken by the company. The document references previous shareholder meeting resolutions and disclosures but does not contain comprehensive financial statements or detailed financial performance data. It is primarily an update on financing activities related to cash management and investment products. The document length is about 5513 characters, which is sufficient for a detailed announcement but does not constitute a full financial report like an Annual or Interim Report. The content fits best under the category of Capital/Financing Update (CAP), as it concerns updates on company fundraising, financing activities, or capital structure changes, specifically the management and redemption of cash management products.
2018-11-21 Chinese
关于使用部分闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Zhuhai Jianfan Biotechnology Co., Ltd. regarding the progress of cash management using part of its idle own funds. It details the purchase of financial products, investment amounts, expected yields, risk management measures, and the impact on the company. The document references prior shareholder meeting resolutions and discloses specific financial product purchases and related risk controls. It is not a full financial report like an Annual Report or Interim Report, nor is it a transcript, audit report, or management change announcement. It is a regulatory announcement about the company's financing activities related to cash management and investment of idle funds. The document length is over 5,000 characters and contains substantive financial information about capital usage and investment products. Therefore, it fits best under Capital/Financing Update (CAP).
2018-11-20 Chinese
关于部分理财产品到期赎回的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the progress of redemption of certain financial products (理财产品) that have matured. It details the amounts, types, and returns of these financial products, as well as the associated risks and measures taken by the company. The document references previous shareholder meeting resolutions and disclosures but does not contain comprehensive financial statements or detailed financial performance data. It is primarily an update on the status of specific financial investments and risk management, not a full financial report or earnings release. The document length is about 5,427 characters, which is sufficient for a detailed announcement but not a full annual or interim report. The content fits best with a Capital/Financing Update (CAP) as it relates to the management and status of the company's cash management and investment activities using idle funds and raised capital. Therefore, the appropriate classification is CAP with high confidence.
2018-11-19 Chinese
关于延长闲置自有资金和募集资金的现金管理期限的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company regarding the extension of the cash management period for idle self-owned funds and raised funds. It includes specifics about investment amounts, types of financial products, approvals by the board and supervisory committees, independent director opinions, and the need for shareholder meeting approval. The document is not a financial report like an annual or interim report, nor is it a transcript, audit report, or earnings release. It is a regulatory announcement about capital management activities and approvals related to the use of funds. It does not contain financial statements or detailed financial performance data but focuses on capital management decisions and disclosures. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (8685 characters) and content support this classification with high confidence.
2018-11-15 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.